Research programme: gene therapies - Audentes Therapeutics

Drug Profile

Research programme: gene therapies - Audentes Therapeutics

Alternative Names: AAV-CASQ2 gene therapy - Audentes; AT 307; AT-003 - Audentes/REGENXBIO

Latest Information Update: 05 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Audentes Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ventricular tachycardia

Most Recent Events

  • 10 Aug 2017 Audentes Therapeutics plans to file an IND application for AT 307 for Ventricular tachycardia (CASQ2-related catecholaminergic polymorphic ventricular tachycardia) by the end of 2017
  • 05 Oct 2015 Preclinical trials in Ventricular tachycardia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top